The DA VINCI Pharmacotherapy Algorithm

Antidepressant Trials:
- **Trial A**: Sertraline (Fluoxetine, Venlafaxine XR, Mirtazapine - if Sertraline previously tried and failed)
- **Trial B**: Untried drug from Trial A Group
- **Trial C**: Untried drug from Trials A and B Groups

### Antidepressants

<table>
<thead>
<tr>
<th>Type</th>
<th>Medication</th>
<th>Dose</th>
<th>Week 1 of medication</th>
<th>Week 2 of medication</th>
<th>Week 3 of medication</th>
<th>Week 4 of medication</th>
<th>Week 5 of medication</th>
<th>Week 6 of medication</th>
<th>Week 7 of medication</th>
<th>Week 8 of medication</th>
<th>Max Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antidepressants</td>
<td>Sertraline</td>
<td>mg AM</td>
<td>25</td>
<td>50</td>
<td>Increase dose by 50 mg every 2-4 weeks depending on tolerability and response</td>
<td>200 mg/day</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fluoxetine</td>
<td>mg AM</td>
<td>10</td>
<td>20</td>
<td>Increase dose by 20 mg every 4 weeks depending on tolerability and response</td>
<td>80 mg/day</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Venlafaxine XR</td>
<td>mg AM</td>
<td>37.5</td>
<td>75</td>
<td>Increase dose by 75 mg every 2-4 weeks depending on tolerability and response</td>
<td>375 mg/day</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mirtazapine</td>
<td>mg QHS</td>
<td>15</td>
<td>30</td>
<td>Increase dose by 15 mg every 2-4 weeks depending on tolerability and response</td>
<td>60 mg/day</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Tactics and Critical Decision Point and Critical Status Plan for the Treatment of Major Depressive Disorder

**STARTING POINT** → **Week 0 (CDP#1) QIDS ≥ 9 Symptomatic**

**PLAN** → Initiate antidepressant medication; adjust dose to lower end of therapeutic dose range or serum level.

**QIDS-C16 SCORE**

<table>
<thead>
<tr>
<th>QIDS &lt; 5 (Remission)</th>
<th>Week 2 of medication</th>
<th>Week 4 of medication</th>
<th>Week 6 of medication</th>
<th>Week 9 of medication</th>
<th>Week 12 of medication</th>
</tr>
</thead>
</table>

**QIDS = 6-8 (Partial Response)**

- Increase dose.
- Switch to another antidepressant.
- Increase current dose and address SEEs.
- Continue current dose and address SEEs.
- Switch to another antidepressant.

**QIDS = 6-8 (SEs intolerable)**

- Decrease dose and continue for 2 additional weeks.
- Switch to another antidepressant.
- Decrease dose and continue for 2 additional weeks.
- Switch to another antidepressant.
- Decrease dose and continue for 2 additional weeks.
- Switch to another antidepressant.

**QIDS ≥ 9 (Non-response)**

- Increase dose.
- Switch to another antidepressant.
- Increase dose.
- Switch to another antidepressant.
- Increase dose.
- Switch to another antidepressant.

**QIDS ≥ 9 (SEs intolerable)**

- Increase dose.
- Switch to another antidepressant.
- Increase dose.
- Switch to another antidepressant.
- Increase dose.
- Switch to another antidepressant.

### Anticholinergics

<table>
<thead>
<tr>
<th>Type</th>
<th>Medication</th>
<th>Dose</th>
<th>Week 1 of medication</th>
<th>Week 2 of medication</th>
<th>Week 3 of medication</th>
<th>Week 4 of medication</th>
<th>Week 5 of medication</th>
<th>Week 6 of medication</th>
<th>Week 7 of medication</th>
<th>Week 8 of medication</th>
<th>Max Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anticholinergics</td>
<td>Naltrexone</td>
<td>mg/day</td>
<td>25</td>
<td>50</td>
<td>50 mg/day</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Acamprosate</td>
<td>mg TID</td>
<td>333</td>
<td>333</td>
<td>333 mg TID</td>
<td>666 mg TID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Topiramate</td>
<td>mg AM</td>
<td>25</td>
<td>50</td>
<td>100 mg/day</td>
<td>150</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Criteria for Anticholinergic Treatment

- Treatment non-Responder will have more than 7 (women) or 14 (men) drinks per week on average.
- More than 1 day on which more than 3 drinks (women) or 4 drinks (men) were consumed over the period of 2 weeks.

### Criteria for Anti-Craving Medication

Treatment non-Responder will have more than 7 (women) or 14 (men) drinks per week on average.
- More than 1 day on which more than 3 drinks (women) or 4 drinks (men) were consumed over the period of 2 weeks.